Cetera Investment Advisers
AUTL

Cetera Investment Advisers’s Autolus Therapeutics AUTL Stock Holding History

Cetera Investment Advisers’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Buy
1,157,324
+28,250
+3% +$44.3K ﹤0.01% 2446
2026
Q1 		$1.56M Buy
1,129,074
+29,324
+3% +$44.5K ﹤0.01% 2502
2025
Q4 		$2.19M Buy
1,099,750
+298,500
+37% +$459K ﹤0.01% 2132
2025
Q3 		$1.31M Buy
801,250
+184,078
+30% +$360K ﹤0.01% 2539
2025
Q2 		$1.41M Buy
617,172
+92,300
+18% +$153K ﹤0.01% 2105
2025
Q1 		$814K Buy
524,872
+168,650
+47% +$342K ﹤0.01% 2434
2024
Q4 		$837K Buy
356,222
+224,222
+170% +$758K ﹤0.01% 2285
2024
Q3 		$479K Sell
132,000
-2,500
-2% -$9.97K ﹤0.01% 2683
2024
Q2 		$468K Buy
134,500
+2,719
+2% +$11.7K ﹤0.01% 2646
2024
Q1 		$841K Buy
131,781
+281
+0.2% +$1.75K ﹤0.01% 2212
2023
Q4 		$847K Sell
131,500
-2,500
-2% -$9.54K 0.01% 1198
2023
Q3 		$312K Sell
134,000
-1,200
-0.9% -$3.42K ﹤0.01% 1699
2023
Q2 		$322K Sell
135,200
-6,400
-5% -$15.2K ﹤0.01% 1695
2023
Q1 		$261K Buy
141,600
+4,000
+3% +$7.82K ﹤0.01% 1787
2022
Q4 		$261K Buy
137,600
+2,200
+2% +$5.56K ﹤0.01% 1743
2022
Q3 		$290K Buy
135,400
+8,400
+7% +$24.9K 0.01% 1285
2022
Q2 		$359K Buy
127,000
+2,700
+2% +$8.22K 0.01% 1297
2022
Q1 		$518K Buy
124,300
+9,550
+8% +$40.2K 0.01% 1127
2021
Q4 		$596K Buy
114,750
+9,650
+9% +$57.9K 0.01% 1081
2021
Q3 		$688K Buy
+105,100
New +$664K 0.01% 944

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cetera Investment Advisers's AUTL Position: Q2 2026 in Review

Cetera Investment Advisers increased its Autolus Therapeutics (AUTL) stake by 2.5% in Q2 2026, buying an estimated $44.3K and bringing the position to 1,157,324 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

Cetera Investment Advisers first reported a position in AUTL in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.19M in Q4 2025. 83 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Cetera Investment Advisers held 1,157,324 shares of Autolus Therapeutics worth $1.85M as of Q2 2026.
  • Cetera Investment Advisers bought 28,250 Autolus Therapeutics shares in Q2 2026, an estimated $44.3K.
  • Autolus Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2446 holding.
  • Cetera Investment Advisers first reported a position in Autolus Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Cetera Investment Advisers's Autolus Therapeutics position peaked at $2.19M in Q4 2025.
  • 83 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.